Battle to get fiercer over local anti-ulcer market

Korean drug makers are expected to wage fiercer campaigns to raise domestic anti-ulcer market share amid forecasts that Ilyang Pharm will emerge as a strong competitor with its Noltec (ilaprazole) new proton pump inhibitor.

Ilyang is accelerating its aggressive marketing activities, publicizing the excellent efficacy of ilaprazole through symposia and clinical study groups, according to sour...